Sunday, August 03, 2014 3:25:38 PM
Below is part of what I got from IR last week:
"Please note that there are several other meaningful developmental milestones to look forward to, including, (1) the announcement of our strategy of MST-188 for the treatment of heart failure; (2) plans to evaluate MST-188 in a trauma model; and (3) plans to report results from a Phase 2 study of AIR001 in pulmonary arterial hypertension and announce our overall clinical strategy for AIR001, among others."
GLTA
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM